Lauren Elman, MD
Professor of Neurology at the Hospital of the University of Pennsylvania and the Pennsylvania Hospital
Director of the Muscular Dystrophy Association Clinic, University of Pennsylvania Medical Center
Director of the Penn Comprehensive Amyotrophic Lateral Sclerosis Center, University of Pennsylvania Medical Center
Associate Director and Clinical Lead of the Translational Center of Excellence, University of Pennsylvania Medical Center
Department: Neurology
Contact information
Pennsylvania Hospital
330 South 9th Street
Philadelphia, PA 19107
330 South 9th Street
Philadelphia, PA 19107
Office: 215-829-6708
Fax: 215-829-6606
Fax: 215-829-6606
Education:
BA (Psychology)
Cornell University, 1994.
MD (Medicine)
Cornell University Medical College, 1998.
BA (Psychology)
Cornell University, 1994.
MD (Medicine)
Cornell University Medical College, 1998.
Post-Graduate Training
Medicine Internship, Hospital of the University of Pennsylvania, 1998-1999.
Neurology Residency, Hospital of the University of Pennsylvania, 1999-2002.
Neuromuscular Fellowship, Hospital of the Universityof Pennsylvania, 2002-2004.
Clinical Research Certificate Program, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 2003-2005.
Medicine Internship, Hospital of the University of Pennsylvania, 1998-1999.
Neurology Residency, Hospital of the University of Pennsylvania, 1999-2002.
Neuromuscular Fellowship, Hospital of the Universityof Pennsylvania, 2002-2004.
Clinical Research Certificate Program, Center for Clinical Epidemiology and Biostatistics, University of Pennsylvania, 2003-2005.
Certifications
American Board of Psychiatry and Neurology, 2003.
American Board of Psychiatry and Neurology, Maintenance of Certification, 2013.
Permanent linkAmerican Board of Psychiatry and Neurology, 2003.
American Board of Psychiatry and Neurology, Maintenance of Certification, 2013.
Selected Publications
C, Maiser S, Walk D, So Y, McCauley JL, Baker MC, Taylor JP, Zuchner S, Rademakers R, van Blitterswijk M, Benatar M.: Shared burden of ultra-rare genetic variants across a spectrum of motor neuron diseases. Transl Neurodegener 14, October 2025.Lee I, Jang G, Cheung YKK, Sherman AV, Johnston WS, Diaz F, Fernandes JAM, Habib AA, Maragakis NJ, Paganoni S, Burke K, Oskarsson B, Shah J, Zinman L, Floeter MK, Ajroud-Driss S, Gwathmey K, Heiman-Patterson T, Jawdat O, Kasarskis EJ, Kisanuki YY, Wymer J, Fournier C, Hayat G, Heitzman D, Lomen-Hoerth C, Pulley MT, Scelsa SN, Walk D, Goutman SA, Shoesmith C, Simmons Z, Sorenson E, Elman L, Harms MB, Hoover BN, Yun RY, Santella RM, Mitsumoto H; PLS NHS Study Group.: Primary Lateral Sclerosis Natural History Study: Primary Lateral Sclerosis Functional Rating Scale and Other Outcomes Assessment. Ann Neurol September 2025.
Spencer BE, Irwin DJ, Van Deerlin VM, Suh E, Lee EB, Elman L, Quinn CC, Amado D, Baer M, Grossman M, Wolk DA, McMillan CT.: Polygenic associations with clinical and neuropathological trait heterogeneity across TDP-43 proteinopathies. medRxiv July 2025.
Austin MA, Supple GE, Carrell S, Quinn C, Elman L, Nazarian S.: Atrial Fibrillation and Flutter in a Contemporary Cohort of Patients With Myotonic Muscular Dystrophy. JACC Clin Electrophysiol May 2025.
Morrison AH, Jimenez JV, Hsu JY, Elman L, Choi PJ, Ackrivo J.: Identifying Daytime Hypercapnia Using Transcutaneous Carbon Dioxide Monitoring in Patients With Amyotrophic Lateral Sclerosis. Muscle Nerve April 2025.
Writing Committee for the HEALEY ALS Platform Trial; Andrews J, Paganoni S, Macklin EA, Chibnik LB, Quintana M, Saville BR, Detry MA, Vestrucci M, Marion J, McGlothlin A, Young E, Chase M, Pothier L, Harkey B, Yu H, Sherman A, Shefner J, Hall M, Kittle G, Connolly MR, Berry JD, D'Agostino D, Tustison E, Giacomelli E, Scirocco E, Alameda G, Locatelli E, Ho D, Quick A, Heitzman D, Ajroud-Driss S, Appel SH, Shroff S, Katz J, Felice K, Maragakis NJ, Simmons Z, Goutman SA, Olney N, Miller T, Fernandes JA, Ilieva H, Jawdat O, Weiss MD, Foster L, Vu T, Ladha S, Owegi MA, Newman DS, Arcila-Londono X, Jackson CE, Swenson A, Heiman-Patterson T, Caress J, Fee D, Peltier A, Lewis R, Rosenfeld J, Walk D, Johnson K, Elliott M, Kasarskis EJ, Rutkove S, McIlduff CE, Bedlack R, Elman L, Goyal NA, Rezania K, Twydell P, Benatar M, Glass J, Cohen JA, Jones V, Zilliox L, Wymer JP, Beydoun SR, Shah J, Pattee GL, Martinez-Thompson J, Nayar S, Granit V, Donohue M, Grossman K, Campbell DJ, Qureshi IA, Cudkowicz ME, Babu S. : Verdiperstat in Amyotrophic Lateral Sclerosis: Results From the Randomized HEALEY ALS Platform Trial. JAMA Neurology April 2025.
Writing Committee for the HEALEY ALS Platform Trial; Berry JD, Maragakis NJ, Macklin EA, Chibnik LB, Quintana M, Saville BR, Detry MA, Vestrucci M, Marion J, McGlothlin A, Stommel EW, Chase M, Pothier L, Harkey BA, Yu H, Sherman A, Shefner J, Hall M, Kittle G, Babu S, Andrews J, D'Agostino D, Tustison E, Scirocco E, Giacomelli E, Alameda G, Locatelli E, Ho D, Quick A, Ajroud-Driss S, Katz J, Heitzman D, Appel SH, Shroff S, Felice KJ, Simmons Z, Miller T, Olney N, Weiss MD, Goutman SA, Fernandes JA Jr, Jawdat O, Owegi MA, Foster L, Vu T, Ilieva H, Newman DS, Arcila-Londono X, Jackson C, Ladha S, Heiman-Patterson T, Caress J, Swenson A, Peltier A, Lewis R, Fee D, Elliott M, Bedlack R, Kasarskis EJ, Elman L, Rosenfeld J, Walk D, McIlduff CE, Twydell P, Young E, Johnson K, Rezania K, Goyal NA, Cohen JA, Benatar M, Jones V, Glass J, Shah J, Beydoun SR, Wymer JP, Zilliox L, Nayar S, Pattee GL, Martinez-Thompson J, Rynders A, Evan J, Evan J, Hartford A, Sepassi M, Ho KS, Glanzman R, Greenberg B, Hotchkin MT, Paganoni S, Cudkowicz ME; HEALEY ALS Platform Trial Study Group.: CNM-Au8 in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial. JAMA February 2025.
Writing Committee for the HEALEY ALS Platform Trial; Shefner JM, Oskarsson B, Macklin EA, Chibnik LB, Quintana M, Saville BR, Detry MA, Vestrucci M, Marion J, McGlothlin A, Heiman-Patterson T, Chase M, Pothier L, Harkey BA, Yu H, Sherman AV, Hall M, Kittle G, Berry JD, Babu S, Andrews J, D'Agostino D, Tustison E, Scirocco E, Giacomelli E, Alameda G, Locatelli E, Ho D, Quick A, Ajroud-Driss S, Katz J, Heitzman D, Appel SH, Shroff S, Felice K, Maragakis NJ, Simmons Z, Miller TM, Olney N, Weiss MD, Goutman SA, Fernandes JA, Jawdat O, Owegi MA, Foster LA, Vu T, Ilieva H, Newman DS, Arcila-Londono X, Jackson CE, Ladha S, Caress JB, Swenson A, Peltier A, Lewis RA, Fee D, Elliott M, Bedlack R, Kasarskis EJ, Elman L, Rosenfeld J, Walk D, McIlduff C, Twydell P, Young E, Johnson K, Rezania K, Goyal NA, Cohen JA, Benatar M, Jones V, Shah J, Beydoun SR, Wymer JP, Zilliox L, Nayar S, Pattee GL, Martinez-Thompson J, Leitner ML, Chen K, Goldberg YP, Cohen Y, Geva M, Hayden MR, Paganoni S, Cudkowicz ME; HEALEY ALS Platform Trial Study Group.: Pridopidine in Amyotrophic Lateral Sclerosis: The HEALEY ALS Platform Trial. JAMA February 2025.
Morganroth J, Bardakjian TM, Dratch L, Quinn CC, Elman LB: Enhancing Clinical Infrastructure for the Delivery of Intrathecal and Genetic Therapies: A Qalsody (Tofersen) Model for Patients With SOD1-ALS. Neurol Clin Pract August 2024.
Rhodes E, Alfa S, Jin HA, Massimo L, Elman L, Amado D, Baer M, Quinn C, McMillan CT: Cognitive reserve in ALS: the role of occupational skills and requirements. Amyotroph Lateral Scler Frontotemporal Degener August 2024.